Advertisement

---

RIGEL PHARMACEUTICALS, INC.

Rigel Will Resume Responsibility for Fostamatinib Program

[2013-06-04] - Fostamatinib at 100mg BID Significantly Improves Rheumatoid Arthritis in Both OSKIRA-2 & OSKIRA-3


Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye

[2013-05-22] - Two Partnered Oncology Programs to Initiate Clinical Trials


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers